PHARMING GROUP NV EUR0.01 revenue breakdown overview

PHARMING GROUP NV EUR0.01 revenue for the last year amounted to 222.26 M EUR, the most of which — 226.91 M EUR — came from its highest performing source at the moment, Recombinant Human C1 Esterase Inhibitor, the year earlier bringing 195.65 M EUR. The greatest contribution to the revenue figure was made by United States — last year it brought PHARMING GROUP NV EUR0.01 221.17 M EUR, and the year before that — 190.38 M EUR.